Subtype assignment can guide pharmacotherapy: SIDD patients benefit from early insulin or insulin secretagogues; SIRD patients from GLP-1 receptor agonists or SGLT2 inhibitors; MOD patients from weight-centric therapies, including incretin-based treatments or bariatric surgery; MARD patients from simple regimens such as metformin with low hypoglycaemia risk; and MEOD patients from intensive early lifestyle or incretin-based interventions [46,47,48]. This evidence concerns the gene INS and Hypoglycemia.